Emerging Markets Earnings Roundup: Merck, Pfizer And Amgen (Part 3)
This article was originally published in PharmAsia News
Pfizer lowers overall growth guidance for emerging markets this year but remains bullish on prospects for growth as EMs become more like mature markets in reimbursement and overall health care policies. Merck meanwhile emphasized cost-cutting measures and Amgen sets its sights on Japan.
You may also be interested in...
Merck Slims R&D Spend, Homes In On Best Assets Like Lambrolizumab
Merck advises that R&D spend for 2013 will be a lower than 2012 as it absorbs a hit from patent expirations of major products. Company stresses that it will prioritize drugs that have potential to shake up clinical practice, like lambrolizumab in oncology and MK-8931 in Alzheimer’s disease.
Pfizer Reorganizes Internally As It Moves Closer To Decision On Splitting Business
Beginning in January 2014, Pfizer is realigning its commercial operations into three organizations, in effect taking the next step on its multi-year deliberation over whether to split up its behemoth business.
Merck Teams With Lycera In Second Autoimmune Deal
The Michigan-based biotech says the latest discovery and development deal with Merck is validation of its ongoing work with the Big Pharma in the field of autoimmune diseases.